-$0.27 Earnings Per Share Expected for Mustang Bio Inc (NASDAQ:MBIO) This Quarter
Brokerages expect Mustang Bio Inc (NASDAQ:MBIO) to post ($0.27) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Mustang Bio’s earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.29). Mustang Bio reported earnings per share of ($0.44) in the same quarter last year, which suggests a positive year-over-year growth rate of 38.6%. The company is expected to issue its next quarterly earnings results on Monday, March 16th.
According to Zacks, analysts expect that Mustang Bio will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.16) to ($1.11). For the next fiscal year, analysts expect that the business will report earnings of ($1.04) per share, with EPS estimates ranging from ($1.29) to ($0.82). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Mustang Bio.
Mustang Bio (NASDAQ:MBIO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.01.
Shares of MBIO stock traded down $0.20 during trading hours on Friday, hitting $3.97. 363,027 shares of the company were exchanged, compared to its average volume of 380,864. The firm has a market cap of $168.74 million, a PE ratio of -3.01 and a beta of 2.29. Mustang Bio has a 1 year low of $2.51 and a 1 year high of $10.20. The company has a quick ratio of 11.82, a current ratio of 11.82 and a debt-to-equity ratio of 0.24. The firm has a fifty day moving average of $3.80 and a 200 day moving average of $3.45.
A number of institutional investors and hedge funds have recently bought and sold shares of MBIO. FNY Investment Advisers LLC increased its position in shares of Mustang Bio by 30.0% during the fourth quarter. FNY Investment Advisers LLC now owns 130,000 shares of the company’s stock valued at $530,000 after purchasing an additional 30,000 shares during the period. Millennium Management LLC bought a new stake in shares of Mustang Bio during the third quarter valued at approximately $95,000. State Street Corp boosted its stake in Mustang Bio by 49.7% in the 3rd quarter. State Street Corp now owns 477,694 shares of the company’s stock valued at $1,557,000 after buying an additional 158,696 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in Mustang Bio in the 3rd quarter valued at $32,000. Finally, Macquarie Group Ltd. acquired a new stake in Mustang Bio in the 2nd quarter valued at $442,000. 26.78% of the stock is owned by hedge funds and other institutional investors.
About Mustang Bio
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See Also: What is quantitative easing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.